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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.010Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular diseases, but the mechanism is
unclear. The pathogenic risk of Lp(a) is associated with elevated plasma concentration, small isoforms
of apolipoprotein [apo(a)], the unique apolipoprotein of Lp(a), and a mimic of plasminogen. Inﬂam-
mation is associated with both the initiation and recovery of cardiovascular diseases, and plasminogen
plays an important role in leukocyte recruitment. Because Lp(a)/apo(a) is expressed only in primates,
transgenic mice were generated, apo(a)tg and Lp(a)tg mice, to determine whether Lp(a)/apo(a)
modiﬁes plasminogen-dependent leukocyte recruitment or whether apo(a) has an independent role
in vivo. Plasminogen activation was markedly reduced in apo(a)tg and Lp(a)tg mice in both peritonitis
and vascular injury inﬂammatory models, and was sufﬁcient to reduce matrix metalloproteinase-9
activation and macrophage recruitment. Furthermore, neutrophil recruitment and the neutrophil
cytokines, CXCL1/CXCL2, were suppressed in apo(a)tg mice in the abdominal aortic aneurysm model.
Reconstitution of CXCL1 or CXCL2 restored neutrophil recruitment in apo(a)tg mice. Apo(a) in the
plasminogen-deﬁcient background and Lp(a)tg mice were resistant to inhibition of macrophage
recruitment that was associated with an increased accumulation of apo(a) in the intimal layer of the
vessel wall. These data indicate that, in inﬂammation, Lp(a)/apo(a) suppresses neutrophil recruitment
by plasminogen-independent cytokine inhibition, and Lp(a)/apo(a) inhibits plasminogen activation
and regulates matrix metalloproteinase-9 activation and macrophage recruitment. (Am J Pathol 2014,
184: 1503e1517; http://dx.doi.org/10.1016/j.ajpath.2014.01.010)Supported by NIH grants, National Heart, Lung, and Blood Institute
grants R01HL078701 and R01HL17964 (J.H.P.) and American Heart As-
sociation grants 09BGIA2050157 and 12SDG9050018 (Y.G.).
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School of Medicine, Philadelphia, PA.Cardiovascular diseases (CVDs) are the leading cause of
death in the United States, and numerous studies document
the close association of inﬂammation in the initiation and
progression of CVD.1,2 Strong evidence establishes elevated
lipoprotein(a) [Lp(a)] is an independent risk factor for
myocardial infarction, ischemic stroke, and peripheral
vascular disease.3,4 Lp(a) is composed of the low-density
lipoprotein (LDL) lipid core, with apolipoprotein (apoB)
tethered to the unique apolipoprotein, apo(a). The patho-
genic mechanism of Lp(a) in CVD is unclear, and unlike
LDL and other lipoproteins, there is no effective therapy to
lower plasma Lp(a).5
Although plasmin is the primary enzyme for the degradation
of ﬁbrin, studies in the plasminogen-deﬁcient (Plg/) mice
have consistently shown abnormalities in leukocyte migrationstigative Pathology.
.in a variety of models [eg, transplant atherosclerosis,6 thio-
glycollate (TG)-induced peritonitis,7,8 myocardial infarc-
tion,9,10 and vascular injury11]. Plasminogen binds to multiple
proteins,12e15 and many of these proteins are also plasmin
substrates. In addition to direct proteolytic action on extracel-
lular matrix components, plasmin activates matrix metal-
loproteinase- 9 (MMP-9), which is a key enzyme for collagen
Huang et aldegradation. Macrophage inﬁltration in the peritonitis and
abdominal aortic aneurysm (AAA) inﬂammatory models re-
quires plasminogen activation of MMP-9.8,9 The goal of this
studywas todeterminewhetherLp(a)/apo(a) interfereswith the
plasminogen-dependent leukocyte recruitment in vivo in
inﬂammation.
As a component of Lp(a), apo(a) contains kringle do-
mains that are homologous to plasminogen. Apo(a) and
plasminogen have lysine-binding sites (LBS) in the kringle
domains that contribute to the competition of Lp(a) and
plasminogen binding to ﬁbrin, cells, and extracellular
matrix.15e17 The LBS in the kringle IV type 10 domain, the
primary LBS of apo(a), is similar, but not identical, to the
LBS of plasminogen.18 Lp(a) binds to cells with both apo(a)
and LDL inhibitable interactions.16 These dual components
of Lp(a) make it difﬁcult to distinguish their roles in vivo.
Lp(a) is found only in humans and nonhuman primates, and
in humans, Lp(a) with small isoforms in high concentration
has the highest pathogenic risk.19,20 To isolate Lp(a) func-
tion from LDL, transgenic mice with a small isoform of
apo(a) in high concentration were generated to investigate
the interference of apo(a) with plasminogen in vivo.
The pathogenic mechanism of Lp(a)/apo(a) is not known.
Herein, we investigate the hypothesis that, as a component of
Lp(a), apo(a) interferes with plasminogen-dependent leuko-
cyte recruitment in inﬂammation. The results indicate that
Lp(a)/apo(a) interferes with the plasminogen/MMP-9 acti-
vation pathway and macrophage recruitment. Apo(a) also has
plasminogen-independent suppression of neutrophil inﬁltra-
tion by inhibition of the release of cytokines, required for
neutrophil emigration. Furthermore, Lp(a) inhibited plas-
minogen andMMP-9 activation andmacrophage recruitment,
but transgenic apo(a) [apo(a)tg] mice in the plasminogen-
deﬁcient background and transgenic Lp(a) [Lp(a)tg] mice
were not resistant to macrophage recruitment when apo(a)
was deposited in the intimal area of the vessel wall.
Materials and Methods
Mice
Plg/ mice were developed, as previously described,7 and
backcrossed over 10 generations into the C57BL/6J back-
ground. Apo(a) transgenic mice were generated with an
apo(a) 6 KIV construct (KIV 5 to 10, plus KV and a
protease-like domain)21 with a liver-speciﬁc promoter22 in a
C57BL/6J background and maintained in Plg/ or Plgþ/þ
background. Plgþ/þ and Plg/ or apo(a)tg:Plgþ/þ and
apo(a)tg:Plg/ mice were maintained by heterozygous
breeding pairs. Mice were genotyped for plasminogen by
PCR.23 Human apoB transgenic mice in the C57BL/6
background were obtained from L. S. Huang (Columbia
University, New York, NY), and genotyped as
described.24,25 Lp(a) double-transgenic mice were generated
by crossing our apo(a)tg mice and human apoB transgenic
mice.25 We conﬁrmed with a nonreducing gel that Lp(a)1504was formed. Apo(a) concentration in plasma was measured
by an enzyme-linked immunosorbent assay (ELISA) that we
veriﬁed by using Western blot analysis. The ELISA used a
polyclonal antibody, V406, and apo(a) standard isolated
from humans.23 Values of apo(a) in the mice ranged from 1
to 6 mmol/L (20 to 100 mg/dL), considered to be pathogenic
in humans.19,20,23 The apo(a) from these transgenic mice
was functionally active, measured in a quantitative immu-
noassay. These mice had lysine binding site activity.26
Plasminogen mutant (Plgmut) mice were obtained from
Victoria A. Ploplis and Francis J. Castellino (University of
Notre Dame, Notre Dame, IN), and genotyped as described.27
All mice were maintained on a C57BL/6J background and
used at 8 to 10 weeks of age. Mice were bred, housed in
sterilized isolator cages, maintained on a 14-hour light/10-
hour dark cycle, and provided with sterilized food and water
at theBiological ResourceUnit of theClevelandClinic Lerner
Research Institute (Cleveland, OH). All animal experiments
were performed in accordancewith protocols approved by the
Cleveland Clinic Institutional Animal Research Committee.
Apo(a) Puriﬁcation
Plasma from apo(a)tg:Plg/ mice was pooled, and apo(a)
was isolated on a mini lysine-Sepharose column (lysine
Sepharose 4B; GE Healthcare, Pittsburgh, PA). The plasma
from apo(a)tg:Plg/ mice has the advantage that Plg will
not interfere with the apo(a) binding to the lysine-
Sepharose. After incubation with plasma overnight at 4C,
the column was washed with PBS four times and the last
wash was with 0.3 mol/L NaCl in PBS and absorbance at
A280 was <0.1. The column was eluted with 0.2 mol/L
ε-aminocaproic acid (Sigma, St. Louis, MO) to release
apo(a). The apo(a) was recovered by dialysis to remove the
ε-aminocaproic acid and concentrated by Amicon Ultra
Centrifugal Filters-50K (Millipore, Billerica, MA).
Assays
Plasminogen activity was measured in 10 mL of plasma and
10 mL of peritoneal lavage in 96-well plates in a total volume
of 250 mL with 0.3 mmol/L S-2251 (S820332; Chromoge-
nixDiapharma, West Chester, OH), without or with 5 IU
urinary-type plasminogen activator (672081; Millipore) in
0.05 mol/L Tris buffer (pH 7.4) containing 0.1 mol/L NaCl.
Plasmin standards ranged from 0 to 10 nmol/L. Plasmin
generation was continually monitored at 405 nm every 10
minutes through hydrolysis of S2251 at 37C for 1 hour and
showed a linear increase. The rate of plasmin generation in
lavage and plasma samples was calculated as OD change/
minute and converted to concentration/minute, according to
the standards. The slope of OD change was linear over
60minutes. Plasma and aorta were collected at 1 or 3 days after
CaCl2-induced AAA. Aortas were homogenized in liquid
nitrogen and extracted by radioimmunoprecipitation assay
lysis buffer (RIPA buffer) containing protease inhibitorajp.amjpathol.org - The American Journal of Pathology
Figure 1 Inhibition of AAA development in apo(a)tg and Plg/ mice.
A: Abdominal aorta diameters measured before CaCl2 treatment and 3 weeks
later. Bars are means  SEM (n Z 6 to 14). Statistical analysis, one-way
analysis of variance, and Dunnett’s posttest were performed. B: Abdominal
aortas collected 3 weeks after CaCl2 treatment. Aorta sections stainedwithH&E
stain,Masson’s trichrome stain for collagen, and Elastica vanGieson (EVG) stain
for elastic lamina from saline-treated sham and CaCl2-treated mice, represen-
tative sections from six mice per genotype. *P< 0.05, **P< 0.01 versus WT.
Original magniﬁcation,10 (B).
Lp(a)/apo(a) and Leukocyte Recruitment(04693159001; Roche, Indianapolis, IN). Aortic protein
concentration was measured by BCA protein assay (23225;
Thermo Scientiﬁc, Rockford, IL). Following the manufac-
turer’s instructions (MCXCL100 and MM200; R&D, Min-
neapolis, MN), CXCL1 and CXCL2 concentrations were
detected by ELISA. MMP-9 activity in the aortic tissues and
peritoneal lavage were examined with a 10% gelatin zymo-
gram gel (EC6175BOX; Life Technologies, Grand Island,
NY). The gels were treated with Renaturing and Developing
Buffer (LC2670 and LC2671; Life Technologies), according
to the manufacturer’s instructions, and then stained with Gel-
Code Blue Stain Reagent (24590; Thermo Scientiﬁc). The
intensities of bands were quantiﬁed by ImageJ software
version 1.1.6 (NIH, Bethesda, MD). THP-1, humanThe American Journal of Pathology - ajp.amjpathol.orgmonocytic cell line, and macrophages were used for the
in vitro cell assays.
Histological, Immunohistochemistry, and
Immunoﬂuorescent Staining
The dissected abdominal aorta was ﬁxed in 4% para-
formaldehyde and embedded in Tissue-Tek CRYO-O.C.T.
Compound (Torrance, CA). Cryostat sections (5 mm thick)
were stained with H&E for histochemical examination, with
Masson’s trichrome for collagen content, and with Elastica
van Gieson for elastic lamina detection. Aorta sections (12
mm thick) were immunostained with mouse neutrophil anti-
body (CL8993AP; Cedarlane Laboratories Ltd, Burlington,
NC) and macrophage antibody Mac-3 (550292; BD Bio-
sciences, San Jose, CA) with a 1:200 dilution. The area of
positive signal and the total area of each section were quan-
tiﬁed using Image-Pro Plus Software version 7.0 (Media
Cybernetics Inc, Silver Spring, MD). Three to four sections
from each mouse were analyzed, and the values were aver-
aged for seven to nine mice. Parafﬁn sections were immu-
nostained with primary anti-apo(a) V406 (1:100), anti-apoB
MB47 (1:100; obtained from L. K. Curtiss, The Scripps
Research Institute, La Jolla, CA), and anti-smooth muscle
actin (1:200; Sigma), and appropriate secondary antibodies,
anti-rabbit conjugated with Alexa 488 (Life Technologies) or
anti-mouse conjugated with Alexa 568, were added.
Results
AAA Formation in Apo(a)tg and Plg/ Mice
To determine whether apo(a), as a component of Lp(a),
interferes with the suppression of plasminogen-dependent
macrophage recruitment, wild-type (WT), plasminogen-
deﬁcient (Plg/), and apo(a)-transgenic [apo(a)tg] mice
were evaluated after CaCl2-induced vascular injury. The
abdominal aorta was dilated by 62% in WT mice, but only
24% in the Plg/ mice and 15% in apo(a)tg mice 3 weeks
after CaCl2 treatment (Figure 1A). No aortic dilation was
observed in saline-treated sham controls of WT, Plg/, or
apo(a)tg mice (Supplemental Figure S1A). Dilation of the
abdominal aorta was accompanied by elevated leukocyte
inﬁltration, thinning of the media layer, and disruption of
elastic lamellae in WT mice (Figure 1B). For the saline-
treated sham group, the vessel structure of Plg/ and
apo(a)tg mice was not different from that for WT mice.
Compared with the sham, increased inﬂammatory cells in
the adventitia of the WT mice vessel wall were observed at
3 weeks after CaCl2 treatment. In contrast, cellular inﬁltra-
tion was not elevated in peri-aortic tissue from Plg/ mice
or apo(a)tg mice. Trichrome staining of sections from WT
mice revealed a loss of arterial architecture and decreased
collagen deposition, whereas Plg/ mice and apo(a)tg mice
remained unchanged. Elastic lamella became fragmented
and ﬂattened in WT mice, but in apo(a)tg and Plg/ mice,1505
Figure 2 Suppressed macrophage recruitment, MMP-9 activation, and plasminogen activation in apo(a)tg mice. A: Abdominal aortas collected 3 weeks
after CaCl2 treatment. Representative aorta sections stained with macrophage antibody Mac-3. Quantiﬁcation of number of macrophages per area from three to
four sections per mouse (nZ 6 to 8). B: Blood monocytes 3 weeks after CaCl2 treatment. C: Aorta active and proMMP-9 in WT and apo(a)tg mice detected on
day 1 by gelatin zymography and quantiﬁed, representative sections. Bars are means plusmn; SEM (nZ 6 to 8), by t-test. D: Plasma was collected at 1 day, 3
days, 1 week, and 3 weeks after CaCl2 treatment. Plasminogen activation monitored as plasmin generation (n Z 4 to 6). Bars are means  SEM. Statistical
analysis, one-way analysis of variance, and Newman-Kuels posttest were performed. E: Representative aorta sections with H&E, Trichrome, EVG staining from
sham and CaCl2-treated Plg
mut mice. F: Abdominal aorta diameters of Plgmut mice measured before CaCl2 treatment and 3 weeks later. Bars are means  SEM
(n Z 6 to 7). Statistical analysis and t-test were performed. *P < 0.05, **P < 0.01, and ***P < 0.001. Scale bar Z 100 mm (A).
Huang et althe elastic lamella was similar to that of the saline-treated
mice (Figure 1B). The inhibition of dilation and lack of
change in the morphological characteristics in the apo(a)tg
mice (with Plg) were similar to those of the Plg/ mice,
suggesting that apo(a) interferes with Plg in the formation of
AAA in the apo(a)tg:Plgþ/þ mice.
Apo(a) Suppresses Macrophage Recruitment and
MMP-9 Activation in AAA
Previously, we found that abdominal aortic injury in plas-
minogen deﬁciency was accompanied by reduced macro-
phage inﬁltration and activation of MMP-9.8 To understand
how apo(a) interfered with plasminogen-mediated inﬂam-
mation, we assessed macrophage migration and MMP-9
activation in apo(a)tg mice. Few macrophages were
observed in the saline-treated mice, because no inﬂamma-
tion was induced. With CaCl2 treatment, macrophage
recruitment to the injured vessel wall, when compared with1506the saline control, was increased to 15% in WT mice, but
was only 4% in apo(a)tg mice (Figure 2A). The percentage
of macrophage was measured by positive Mac-3 area to the
total aortic area. In contrast, blood monocytes were fourfold
higher in apo(a)tg mice than in WT mice (Figure 2B) and
remained higher at 3 weeks (3.7-fold higher). The accu-
mulation of monocytes in the blood and reduced macro-
phages in the injured tissue of apo(a)tg mice suggested that
migration from blood through the vessel wall was impaired.
MMP-9 activity was determined in the abdominal aorta of
WT and apo(a)tg mice. The proenzyme of MMP-9
(ProMMP-9) was not different in WT and apo(a)tg mice,
and Western blot analysis of the plasma also indicated there
was no difference in total MMP-9 (Supplemental
Figure S1B). Active MMP-9 and proMMP-9 were deter-
mined by zymography (proMMP-9, 105 kDa; and actMMP-
9, 95 and 88 kDa) in the aorta 1 day after treatment.
ActMMP-9 was 37% lower in apo(a)tg mice than WT mice,
and the ratio of actMMP-9/proMMP-9 was signiﬁcantlyajp.amjpathol.org - The American Journal of Pathology
Figure 3 Apo(a) inhibited plasminogen-inducedMMP-9 activation andmacrophage migration in vitro. A: THP-1 cells incubated with 50 nmol/L of plasminogen
or plasminogen with 100 to 400 nmol/L of apo(a) for 48 hours are shown. Zymography and intensity of secreted MMP-9 in conditioned media, representative of
three independent experiments. B: Macrophages were isolated from mouse peritoneal lavage seeded on transmembrane-coated collagen IV inserts, and macro-
phage number was calculated. Cells incubated with 50 nmol/L plasminogen and 200 nmol/L apo(a) with proMMP-9 or actMMP-9 in the top chamber overnight.
C: Boyden chamber assay macrophage number for migrated cells stimulated with 50 nmol/L plasmin and 200 nmol/L apo(a) with MMP inhibitor, GM6001, or MMP-
9eneutralizing antibody.D:Macrophage invasion through the transmembrane-coatedMatrigel inserts. Three independent experiments performed in triplicate. Bars
aremeans SEMof each averaged experiment. Statistical analysis, one-way analysis of variance, and Dunnett’s posttest were performed. E: Representative confocal
image of colocalization (yellow) of 50 nmol/L apo(a) (green) and 50 nmol/L plasminogen (red) binding on THP-1 cells. THP-1 cells were incubatedwith plasminogen
and apo(a) in the media for 16 hours, and cells were washed before ﬂuorescent staining. *P < 0.05, **P < 0.01, and ***P < 0.001. Scale barZ 10 mm (E).
Lp(a)/apo(a) and Leukocyte Recruitmentdecreased in apo(a)tg mice compared with WT mice
(Figure 2C). Reduced MMP-9 activation also supported the
observation in apo(a)tg mice that collagen was protected
from degradation (Figure 1B). The reduced macrophage
recruitment and activation of MMP-9 in apo(a)tg mice was
similar to that found for Plg/ mice in the AAA model.8
Taken together, these results indicate that apo(a) inhibits
MMP-9 activation and macrophage recruitment and,
consequently, AAA development.
Plasmin Activity Is Impaired in Apo(a)tg Mice in an
AAA Inﬂammatory Model
To determine whether the inhibition of macrophage
recruitment and MMP-9 activation in apo(a)tg mice was
dependent on plasminogen activation, the plasmin genera-
tion rate was determined. In untreated WT and apo(a)tg
mice, plasminogen activation was not different in the
plasma (Supplemental Figure S1C). However, with CaCl2
treatment, plasma plasminogen activation in apo(a)tg mice
was signiﬁcantly reduced compared with WT mice during
AAA development (Figure 2D), suggesting that apo(a)
interfered with the activation of plasminogen.
Plasmin has both signaling and proteolytic activity, and
apo(a) may inhibit the signaling and/or proteolytic activity of
plasminogen to inhibit AAA formation. Plgmut mice have aThe American Journal of Pathology - ajp.amjpathol.orgsingle amino acid mutation (Ser 743 to Ala) in the protease
domain and lack proteolytic activity, but retain signaling ac-
tivity.27 The aorta diameter dilated 20% in Plgmut mice after
CaCl2 treatment and was signiﬁcantly lower compared with
WTmice (Figure 2F). Themorphological characteristics of the
Plgmut mice were similar to those of Plg/ mice (Figures 1B
and 2E) and suggest that plasmin activity is required for the
AAA formation. The inhibition of dilation and lack of changes
inmorphological features in apo(a)tgmicewere also similar to
Plgmut mice and suggest apo(a) may inhibit plasmin proteo-
lytic activity rather than plasminogen signaling. Li et al28 re-
ported plasmin activation of Akt, extracellular signale
regulated kinase, and c-Jun kinase pathways in THP-1 mac-
rophages, but these pathways were not different in apo(a)tg
mice compared with WT mice (Supplemental Figure S2A).
The prevention ofAAA in Plgmutmice suggested plasminogen
proteolytic activity is required for AAA development. Apo(a)
tg mice were also protected from AAA. In addition, inhibition
of the plasmin proteolytic activity by apo(a) may account for
the reduced MMP-9 activation.
To determine whether monocyte/macrophage chemokines
were reduced in the apo(a)tg mice and contributed to the
reduced recruitment into the aorta, CCL2, the primary
monocyte/macrophage chemoattractant, was measured in the
plasma of the sham- and CaCl2-treated mice at 1 day and 3
weeks (Supplemental Figure S2, B and C). CCL2 was not1507
Figure 4 Aorta dilation was similar inWT and apo(a)tg:Plg/mice.A: Change in abdominal aorta diameter measured before CaCl2 treatment and 3weeks later
(nZ 9). B: Cell inﬁltration, collagen degradation, and elastic lamina disruption 3 weeks after CaCl2 treatment (representative sections shown). C: Representative
sections of macrophages immunostained (Mac-3) in injured aorta 3 weeks after CaCl2 treatment (nZ 3 to 9). Macrophages are given as percentage total area.
D:MMP-9 activity assessed in the peritoneal lavage 72 hours after TG injection (nZ 3). E: Deposition of vessel wall apo(a) before and 3weeks after CaCl2 treatment
(nZ 4). AeE: Bars are means SEM. Statistical analysis, one-way analysis of variance, and Newman-Kuels posttest were performed. *P< 0.05, **P< 0.01, and
***P < 0.001. Scale barZ 200 mm (C). EVG, Elastica van Gieson; SMA, a-smooth muscle actin (a marker for smooth muscle cells).
Huang et aldifferent between WT and apo(a)tg sham or CaCl2-treated
mice 1 day after treatment. However, at 3 weeks after treat-
ment, plasma CCL2 was nearly threefold higher in apo(a)tg
mice than WT mice. Expression of Ccl2 mRNA, determined
by quantitative RT-PCR in the aorta of WT and apo(a)tg mice
1 day after sham and CaCl2 treatment, was twofold higher in
the apo(a)tg mice than WT mice. Expression of Ccl3 mRNA,
also a monocyte/macrophage chemoattractant, was also
increased in apo(a)tg mice compared with WT mice
(Supplemental Figure S2, D and E). Thus, a decrease in the
monocyte/macrophage chemoattractants could not account
for reduced macrophage recruitment in the apo(a)tg mice.
Apo(a) Inhibits MMP-9 Activation and Macrophage
Migration in Vitro
To understand if apo(a), as a component of Lp(a), inhibits
MMP-9 activation directly or competes with plasminogen to
inhibit MMP-9 activation, THP-1 cells were incubated with
increasing concentrations of apo(a), from 100 to 400 nmol/L,
in the presence of 50 nmol/L plasminogen. Plasminogen and
plasmin enhanced MMP-9 activation compared with the
control, and apo(a) alone did not affect MMP-9 activation1508(Figure 3A). Plasminogen-induced MMP-9 activation was
inhibited by apo(a) in a dose-dependent manner. MMP-9
activation was remarkably diminished by adding >200
nmol/L concentrations of apo(a) to 50 nmol/L plasminogen.
However, 50 nmol/L plasmin-inducedMMP-9 activationwas
not affected with addition of 200 nmol/L apo(a), suggesting
that apo(a) suppressed conversion of plasminogen to plasmin.
To determine whether apo(a) suppresses plasminogen-
mediated cell migration or invasion in vitro, primary mac-
rophages were isolated from mouse peritoneal lavage. The
Boyden chamber was coated with collagen IV for migration
assay (Figure 3, B and C) or with Matrigel for invasion
assay (Figure 3D). Apo(a), plasminogen, and plasmin were
added in the top chamber, with the chemoattractant MCP-1
in the bottom chamber. Both plasminogen and actMMP-9
markedly promoted macrophage migration, compared with
the control (media only). Plasminogen-stimulated migration
was decreased by 50% with apo(a) addition. This inhibition
was restored by actMMP-9, but not proMMP-9 (Figure 3B).
Interestingly, plasmin promoted cell migration as well, but
was not inhibited by apo(a) addition. The MMP inhibitor,
GM6001, or MMP-9eneutralizing antibody signiﬁcantly
reducedmigration in the presence of plasminogen and apo(a),ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Suppressed neutrophil recruitment and CXCL1 and CXCL2 expressed in CaCl2-treated aorta of apo(a)tg mice. A: Neutrophils in the vessel wall 3
days after CaCl2 treatment, with three sections for each mouse (nZ 5 to 8 mice). B: Apoptotic cells in injured aorta at day 3. WT, apo(a)tg, Plg
/, and apo(a)
tg:Plg/ mice are shown (P > 0.05, ns). C: Neutrophil number in blood at day 3. D: Plasma CXCL1 and CXCL2 at 1 and 3 days after CaCl2 treatment. E: CXCL1
and CXCL2 in aortas collected at day 1 after saline (sham control) or CaCl2 treatment and homogenized. Statistical analysis, one-way analysis of variance, and
Dunnett’s posttest were performed. *P < 0.05, **P < 0.01. Scale bar Z 200 mm (A). PMN, polymorphonuclear leukocyte.
Lp(a)/apo(a) and Leukocyte Recruitmentindicating MMP-9 activation was not directly modulated by
apo(a) but through plasminogen activation (Figure 3C). In the
invasion assay, plasminogen promoted THP-1 cell invasion
that was inhibited by apo(a) addition, but plasmin-stimulated
invasionwas not suppressed by apo(a) (Figure 3D), consistent
with the observations in the migration assay.
Taken together, these results indicate that apo(a) inhibits
plasminogen activation and MMP-9 activation, and macro-
phage migration or invasion was consequently impaired. We
demonstrated plasminogen-regulated macrophage migration
was suppressed by apo(a) both in vivo and in vitro. Syrovets
et al29 reported Lp(a) and apo(a) were chemoattractants for
monocytes and promoted cell migration in vitro. In their
experiments, they added apo(a)/Lp(a) to the bottom chamber
to attract THP-1 cells. We added apo(a) to the top chamber,
and apo(a) alone did not affect migration. However, apo(a)
blocked plasminogen (also added to the top chamber) activity
and, consequently, inhibited macrophage migration induced
by plasminogen. Our results showed that macrophage
recruitment was inhibited in apo(a)tg mice by CaCl2-induced
AAA inﬂammation, and this function acts through apo(a)-
regulated plasminogen and MMP-9 activity ablation.
Numerous studies demonstrate that plasminogen activa-
tion occurs most efﬁciently bound to the cell membrane,
rather than in solution. Apo(a) competes with plasminogen
binding to cells in vitro, but whether apo(a) and plasmin-
ogen bind to the same site is not clear. By incubating THP-1
cells with 50 nmol/L plasminogen and 50, 100, or 200 nmol/
L apo(a), we observed apo(a) and plasminogen colocalizedThe American Journal of Pathology - ajp.amjpathol.orgon the cells, implying apo(a) may interact with plasminogen
receptors to suppress plasminogen activation on the cell
surface (Figure 3E).
Apo(a) with Plasminogen Deﬁciency Promotes
Macrophage Recruitment
To determine the role of apo(a) in the plasminogen-deﬁcient
background, macrophage recruitment and susceptibility to
aneurysm formation were assessed in apo(a)tg:Plg/ mice.
The apo(a)tg:Plg/ mice were susceptible to AAA for-
mation, similar to the WT mice (Figure 4A). In the apo(a)
tg:Plg/ mice, the dilation of the aorta and the vessel ar-
chitecture were similar to WT mice (Figure 4B), and there
was no difference between the WT and apo(a)tg:Plg/
mice in the saline-treated control aorta (Supplemental
Figure S1A). Macrophage recruitment and MMP-9 activa-
tion were not different in apo(a)tg:Plg/ mice compared
with WT mice (Figure 4, C and D), suggesting apo(a) in the
absence of plasminogen promoted MMP-9 activation and
macrophage migration by a noneplasmin-dependent
mechanism to promote AAA formation by a plasminogen-
independent pathway.
To test where the apo(a) accumulated in the injured aorta
of the apo(a)tg:Plg/ mice, sections were immunostained
(Figure 4E) and apo(a) was found in the intimal layer. In
apo(a)tg:Plg/ mice without CaCl2 treatment, apo(a) was
found primarily in the adventitial layer. The results from
these mice suggest that the accumulation of apo(a) in the1509
Figure 6 Inhibition in WT mice and restoration
in apo(a)tg mice of cytokines and AAA. AeD: WT
mice treated with IgG, anti-CXCL1, or anti-CXCL2
antibodies at 0 to 2 days after CaCl2 treatment.
Neutrophils in aortas collected at day 3. A:
Representative images. B: Neutrophil number in
aorta, mean of four images per mouse (nZ 3 to 4
mice per group). C: Diameter measured both before
CaCl2 treatment and 3 weeks later. D: H&E- and
EVG-stained abdominal aorta sections; arrows
indicate fragmented elastic lamina. EeH: Apo(a)tg
mice injected with saline, cytokine CXCL1, or CXCL2
at 0 to 2 days after CaCl2 treatment. E: Neutrophils
in aorta collected at day 3. F: Neutrophil number
quantiﬁed. G: Aorta diameter measured both
before CaCl2 treatment and 3 weeks later. H:
Increased cell inﬁltration and elastic lamina frag-
mentation. Statistical analysis, one-way analysis
of variance, and Dunnett’s posttest were per-
formed. *P < 0.05, **P < 0.01, and
***P < 0.001. Original magniﬁcations: 20 (D
and H); 10 (E). EVG, Elastica van Gieson; PMN,
polymorphonuclear leukocyte.
Huang et alintimal layer of injured aorta may accelerate with CaCl2-
induced AAA formation.
Neutrophil Recruitment and Cytokines Are Suppressed
in Apo(a)tg Mice
Neutrophils are among the ﬁrst cells recruited during
inﬂammation, and depletion in animal models inhibits AAA
formation.30 Previously, we reported that apo(a) inhibited
neutrophil recruitment in TG-induced peritonitis and was
not plasminogen dependent. To investigate the modulation
of apo(a) in neutrophil recruitment in the AAA vascular
injury model, neutrophils were determined in the injured
aorta. Initially, neutrophils were measured in WT mice aorta
to determine the time course of recruitment. Neutrophils
were highest at 1 day after CaCl2 treatment and declined to
undetectable by day 6 (Supplemental Figure S3A). Thus,
neutrophils were examined at 1 and 3 days after CaCl2
treatment in both aorta and circulation in WT, apo(a)tg,1510Plg/, and apo(a)tg:Plg/ mice. At day 1, neutrophil
recruitment in the aorta of apo(a)tg mice was not different
from that in WT mice (Supplemental Figure S3, B and C).
At day 3, neutrophils in the aorta adventitia of apo(a) mice
were 2.3% (of aortic area), signiﬁcantly lower than 6.6% in
WT mice (P < 0.01). Neutrophils were also less in the aorta
of apo(a)Plg/ mice (2.6%). However, neutrophil recruit-
ment in Plg/ mice was equivalent to that in WT mice
(Figure 5A). Apo(a) inhibited neutrophil recruitment in
either a WT or Plg/ background. Consistent with the
ﬁndings in the peritonitis inﬂammatory model, plasminogen
does not affect neutrophil number at the early stages of
inﬂammation, and apo(a) suppresses neutrophil recruitment
independent of plasminogen. However, circulating neutro-
phils in apo(a)tg mice at day 3 were twofold higher than in
WT mice, but did not remain signiﬁcant at 3 weeks (WT
versus apo(a)tg mice, 0.36  0.12 versus 0.69  0.15). The
circulating monocytes in apo(a)tg mice were not only
signiﬁcantly higher at 3 weeks, but were also higher at dayajp.amjpathol.org - The American Journal of Pathology
Figure 7 Macrophage recruitment and plasminogen/MMP-9 activation impaired in Lp(a)tg mice in the TG peritonitis model. A: Peritoneal lavage collected
at 6, 24, 48, and 72 hours after TG injection, with macrophages measured by non-speciﬁc esterase assay (nZ 5 to 9 for each genotype at each time point). B:
Peritoneal lavage plasmin activity. C: Representative zymogram gel of lavage. D and E: Band intensity quantiﬁed from three zymogram gels (lavage samples
from three mice per genotype at each time point were run on three gels separately). F: Ratio of actMMP-9/proMMP-9. Bars are means  SEM. Statistical
analysis, one-way analysis of variance, and Dunnett’s posttest were performed. *P < 0.05, **P < 0.01, and ***P < 0.001 when compared to WT at same time
point.
Lp(a)/apo(a) and Leukocyte Recruitment3. The elevated circulating leukocytes suggest that, despite
the reduced recruitment to the injured aorta, systemic
inﬂammation may be prolonged in the apo(a)tg mice.
The apo(a) suppression of neutrophils may be due to
reduced entry into the injured vessel wall or increased exit
from the tissue. Apoptotic cells were not different in the
abdominal aorta of WT and apo(a)tg, Plg/, or apo(a)
tg:Plg/ mice at day 3 (Figure 5B). More neutrophils in the
circulation were observed in apo(a)tg mice than in WT
mice, suggesting that the entry into the vessel wall was
impaired (Figure 5C).
CXCL1 and CXCL2, neutrophil chemoattractants, are
required for neutrophil recruitment.31,32 We measured
CXCL1 and CXCL2 in the circulation and injured aorta.
Circulating CXCL1 and CXCL2 were not different in WT
and apo(a)tg mice at 1 or 3 days after CaCl2 treatment
(Figure 5D). Compared with the saline-treated mice,
CXCL1 and CXCL2 in the abdominal aorta were enhanced
by more than ﬁvefold in WT mice with CaCl2 treatment at
day 1. Although neutrophil numberwas equivalent inWT and
apo(a)tgmice,WT cytokineswere signiﬁcantly higher than in
apo(a)tg mice, with CXCL1 fourfold higher and CXCL2
twofold higher in aortic tissue at day 1 after CaCl2 treatment
(Figure 5E). Impaired neutrophil recruitment was observed in
apo(a)tg mice at day 3 as a consequence of decreased cyto-
kines detected at day 1. Cytokines in the apo(a)tg:Plg/mice
were similar to those in the apo(a)tg mice in both the plasma
and aorta at days 1 and 3 (data not shown), conﬁrming that
apo(a) regulation of CXCL1/CXCL2 was independent of
plasminogen. The cytokine expression in the injured tissue,
but not in plasma, was different between WT and apo(a)tg
mice, implying suppressed CXCL1 and CXCL2 in the aortic
tissue were responsible for impaired neutrophil recruitment in
the apo(a)tg mice.The American Journal of Pathology - ajp.amjpathol.orgAAA Formation in WT Mice Is Prevented with CXCL2
Neutralization
To investigate the role of CXCL1 and CXCL2 in AAA
formation, neutralizing antibodies to CXCL1 or CXCL2
were injected into WT mice daily for 3 days after CaCl2
treatment. The neutrophil recruitment was reduced by
threefold in the WT mice injected with CXCL1 or CXCL2
neutralizing antibody, compared with IgG injection control
(Figure 6, A and B). AAA formation was blocked with
CXCL2 antibody, but not CXCL1 antibody, at 3 weeks in
WT mice. The aorta dilation of mice injected with CXCL1
antibody was similar to that of the IgG-injected mice. In
contrast, the aorta dilation was completely abolished in the
mice with CXCL2 antibody injection (Figure 6C and
Supplemental Figure S3D). Although diminishing CXCL1
or CXCL2 signiﬁcantly suppressed neutrophil recruitment,
only the injection of CXCL2 antibody inhibited AAA for-
mation, protecting mice from elastic lamina disruption and
AAA formation (Figure 6D).Reconstitution of Cytokines CXCL1 and CXCL2 Restores
AAA Formation in Apo(a) Mice
CXCL1 and CXCL2 expression in the aorta of apo(a)tg
mice was lower than in WT mice in the AAA model
(Figure 5A). To determine whether restoration of CXCL1
and CXCL2 in apo(a)tg mice was sufﬁcient to restore
AAA formation, CXCL1 or CXCL2 was injected. Either
CXCL1 or CXCL2 injection enhanced neutrophil recruit-
ment to the injured aorta of apo(a)tg mice (Figure 6, E and
F). CXCL1 or CXCL2 signiﬁcantly restored neutrophil
recruitment compared with the saline control (P < 0.05)1511
Figure 8 AAA development in Lp(a)tg mice. A and B: AAA 3 and 6 weeks after CaCl2 treatment. A: Aorta dilation. B: Histochemical staining and
representative aorta sections from WT, Lp(a)tg AAA-resistant (AAA), or susceptible (AAAþ) mice. The fragmented laminae (arrow) in the intimal aorta was
observed in WT or Lp(a) AAAþ mice but not in Lp(a) AAA mice. C: Plasminogen activation in plasma of untreated or CaCl2-treated (at 1 week) WT and Lp(a)tg
mice (left panel). Statistical analysis, by t-test (ns, P > 0.05). Plasminogen activation in plasma in WT, AAA, or AAAþ Lp(a)tg mice at 6 weeks (nZ 7 to 9)
(right panel). D: Macrophages stained with Mac-3 in aorta collected at 3 or 6 weeks after CaCl2 treatment. A dashed line marked the inner boundary of the
vessel. Percentage Mac-3þ cells per area quantiﬁed from three sections per mouse (n Z 3 to 5 mice per group). Bars are means  SEM. Statistical analysis,
one-way analysis of variance, and Newman-Kuels posttest were performed. E: Plasma of Lp(a)tg mice collected at 6 weeks after CaCl2 treatment. Top panel,
analyzed with a nonreducing gel. Apo(a) immunoblotting of free apo(a) and Lp(a) complex. Circulating apo(a) measured by ELISA and concentration (mg/dL)
indicated at the bottom of gel. Bottom panel, Western blot analysis of plasma with reducing gel and immunostained for apo(a) or apoB. Bars are
means  SEM. Statistical analysis, by t-test (ns P > 0.05). *P < 0.05, **P < 0.01. Original magniﬁcation, 10 (B). Scale barZ 100 mm (D). lu, Lumen area.
Huang et al(Figure 6F). Within 3 weeks after CaCl2 treatment, AAA
was severe in the apo(a)tg mice with CXCL1 or CXCL2
injection compared with saline injection. The aorta dilation
in the apo(a)tg mice rescued with CXCL1 or CXCL2
was similar to that in WT mice (Figure 6G). CXCL1 and
CXCL2 reconstitution also promoted inﬂammatory cell
inﬁltration, evident with H&E staining of the aorta,
and the elastic lamina fragmentation in apo(a)tg mice
(Figure 6H). In summary, both CXCL1 and CXCL2 efﬁ-
ciently restored AAA formation in apo(a)tg mice. In
conclusion, apo(a) suppressed neutrophil recruitment by
inhibiting the expression of CXCL1/CXCL2 in the injured
aorta.
Lp(a) and Apo(a) Inhibit Macrophage Recruitment and
MMP-9 Activation in Peritonitis
Apo(a) circulates in the plasma as free apo(a) or bound to
LDL as Lp(a). To determine whether our ﬁndings in the
apo(a)tg mice were also present in Lp(a)tg mice, Lp(a)tg
mice were assessed in the TG-induced peritonitis and the1512CaCl2-induced AAA formation. The lavage was collected
from WT, apo(a)tg, and Lp(a)tg mice at time points of 6,
24, 48, and 72 hours after TG injection. In WT mice,
macrophage recruitment to the peritoneal cavity gradually
increased and peaked at 72 hours. In contrast, macrophages
in the lavage were reduced by 50% in apo(a)tg mice and by
40% in Lp(a)tg mice (Figure 7A); plasmin generation in
apo(a)tg and Lp(a)tg mice was 50% to 70% lower than in
WT mice at 6 to 72 hours after TG injection, suggesting
plasminogen activation was suppressed by apo(a)
(Figure 7B). MMP-9 activation was detected in the lavage
by zymography of proMMP-9 (105 kDa) and actMMP-9
(95 and 88 kDa). ProMMP-9 was not signiﬁcantly
different in WT and apo(a)tg mice (Figure 7D). Compared
with WT mice, actMMP-9 in apo(a)tg and Lp(a)tg mice was
signiﬁcantly lower at each time point from 6 to 72 hours
and was reduced by 50% at 48 hours (Figure 7E). In WT
mice, the ratio of actMMP-9/proMMP-9 increased by 2.5-
fold at 48 hours compared with 6 hours, but in apo(a)tg
and Lp(a)tg mice, this peak did not occur (Figure 7F). The
ratio of actMMP-9/proMMP-9 was signiﬁcantly lower inajp.amjpathol.org - The American Journal of Pathology
Figure 9 Apo(a) and apoB localization in aorta
of Lp(a)tg mice with CaCl2 treatment. A: Apo(a)
localization in aorta of untreated or CaCl2-treated
(3 weeks) apo(a)tg and Lp(a)tg (AAA and AAAþ)
mice. Aorta immunostained for apo(a) (green),
a-smoothmuscle actin (SMA; red), and merged with
DAPI. Dashed line delineates the inner boundary of
the vessel. Apo(a) expression in intimal/medial or
adventitial area quantiﬁed as percentage of total
apo(a) in section. Bars are means  SEM (nZ 6).
Apo(a) and apoB colocalization in vessel wall of
AAA Lp(a)tg mice (a) and AAAþ Lp(a) mice (b and
c) 3 weeks after CaCl2 treatment. B: Apo(a) and
apoB colocalization indicated as arrows in the
adventitial aorta of AAA Lp(a) mice (a) 3 weeks
after CaCl2 treatment (top panel). Representative
images of AAAþ Lp(a) mice with colocalization of
apo(a) and apoB indicated by arrows in the media
layer (middle panel) or both intimal and adven-
titial layers (bottom panel). Scale bars: 100 mm
(A); 50 mm (B). ad, Adventitial boundary; lu,
lumen.
Lp(a)/apo(a) and Leukocyte Recruitmentapo(a)tg mice, indicating that the activation but not the
expression was decreased (Figure 7F). The response of the
Lp(a)tg mice to the inﬂammatory stimulus was analogous to
the response in the apo(a)tg mice, suggesting that the Lp(a)
response was mediated by the apo(a) component.
AAA Formation in Lp(a)tg Mice
Because our study suggests apo(a) inhibits AAA formation,
we also performed AAA on Lp(a)tg mice. Interestingly, 8 of
16 Lp(a)tg mice had a dilated aorta, similar to the WT mice,
and the other 8 mice showed little dilation, similar to apo(a)
tg mice. The phenotypes of Lp(a)tg mice were separated
into two groups, resistant to AAA (AAA) and prone to
AAA (AAAþ). To determine whether some mice needed a
longer time to develop the aneurysm, the post-surgery time
was extended to 6 weeks. In another group of Lp(a)tg mice,
58% (7 of 12) of the mice formed the aneurysm. Aortic
dilation of seven Lp(a)tg mice was more like WT mice, and
minimal dilation was observed in the other ﬁve Lp(a)tg mice
(Figure 8A).
Examination of the aorta tissue sections of Lp(a)tg mice
collected 3 or 6 weeks after CaCl2 treatment revealed that
only the mice that formed an aneurysm [AAAþ Lp(a)tg
mice] had increased cell inﬁltration and disrupted elastic
lamina, similar to WT mice. In the Lp(a)tg mice that didThe American Journal of Pathology - ajp.amjpathol.orgnot form an aneurysm [AAA Lp(a)tg mice], the reduced
cell inﬁltration and the vessel architecture were similar to
apo(a)tg mice (Figure 8B). Plasminogen activation was
signiﬁcantly reduced in Lp(a)tg mice after CaCl2 treat-
ment, compared with WT mice. AAA and AAAþ Lp(a)tg
mice did not show any difference in plasminogen activa-
tion 6 weeks after CaCl2 treatment (Figure 8C). Macro-
phage recruitment was also assessed in WT and Lp(a)tg
mice. At 3 weeks, macrophages were not different in the
arterial wall of WT and AAAþ Lp(a)tg mice, but were
reduced by twofold in AAA Lp(a)tg mice, suggesting
macrophage recruitment contributed to AAA formation in
Lp(a)tg mice. At 6 weeks, macrophages were also signif-
icantly lower in AAA Lp(a)tg mice than WT and AAAþ
Lp(a)tg mice (Figure 8D). Thus, AAAþ Lp(a)tg mice had
the potential to develop AAA, such as the WT mice, and
AAA Lp(a)tg mice were more like apo(a)tg mice that
were protected from AAA formation.
To determine whether the distribution of the apo(a) in the
mice determined susceptibility to AAA, plasma from CaCl2-
treated Lp(a)tg mice was subjected to Western blot analysis
with nonreduced conditions, and there was no difference
between free and bound apo(a) in the AAA and AAAþ
Lp(a)tg mice. Reduced apo(a) or apoB was also not different
between two groups (Figure 8E). Fluorescent immunostain-
ing of the aorta indicated that>90% of apo(a) was located in1513
Figure 10 Apo(a) regulation ofmacrophage recruitment in inﬂammation.
Apo(a) acts with plasminogen-dependent and plasminogen-independent
effects on macrophage recruitment and AAA formation. Plasminogen-
dependent pathway: Apo(a) inhibits plasminogen activation, MMP-9 activa-
tion, macrophage migration, and AAA formation. Plasminogen-independent
pathway: Apo(a) inhibits plasminogen activation, but not MMP-9 activation,
macrophage migration, or AAA formation.
Huang et althe adventitial layer of apo(a)tg mice before or after CaCl2
treatment. a-Smooth muscle actin was assessed to delineate
the medial layer. In untreated Lp(a)tg mice, apo(a) was also
localized predominately in the adventitia, as found in the
apo(a)tg mice. With CaCl2 treatment, in AAA
 Lp(a)tg mice,
apo(a) was localized in the adventitia, whereas AAAþ Lp(a)
tg mice had more apo(a) accumulated in the intimal and
medial layers compared with the adventitial layer
(Figure 9A). In AAAþ Lp(a)tg mice, apo(a) was deposited in
the intimal layer, where the elastic lamina was fragmented.
The difference in susceptibility for AAA between AAA and
AAAþ Lp(a) mice could be explained by apo(a) localization
in the vessel wall. In apo(a)tg mice and AAA Lp(a)tg mice,
the vessel wall was intact and may be the reason they were
protected from apo(a) deposition in the intimal/medial layer.
Apo(a) accumulation was accelerated in the intimal layer
of injured tissue in AAAþ Lp(a)tg mice and may lead to
the degradation of the elastic lamina and dilation of the
vessel. The AAAþ Lp(a)tg mice are similar to the apo(a)
tg:Plg/mice that also formed AAAwith degradation of the
elastic lamina, similar to WT mice. In the apo(a)tg:Plg/
mice, apo(a) also localized to the intimal/medial area. The
formation of the AAA in the AAAþ Lp(a)tg mice (reduced
plasminogen activation) and apo(a)tg:Plg/ mice (no plas-
minogen) suggests apo(a) acts independent of plasminogen.
ApoB was also detected in the arterial wall, and localized in
each layer of aorta from intimal to adventitial. Because apo(a)
dominated in the adventitial layer of AAA Lp(a)tg mice, the
colocalization of apo(a) and apoB [Lp(a) complex] was also
observed predominantly in the adventitia. AAAþ Lp(a)tg mice
had apo(a) and apoB colocalized in adventitia and the intimal
and medial layers (Figure 9B), indicating that Lp(a) localiza-
tion in the intimal/media layer, but not the adventitial layer,
was related to AAA incidence. However, the increased apo(a)
accumulation in the injured intimal and medial layers may
accelerate fragmentation of the elastic lamina and dilation of1514the aorta that speciﬁcally occurred in AAAþ Lp(a)tg mice.
Thus, Lp(a)/apo(a) exhibit both plasminogen-dependent and
plasminogen-independent effects on AAA formation.
Discussion
Elevated Lp(a) is an independent risk factor for cardiovascular
and inﬂammatory diseases.3,4 However, the pathophysiological
role of Lp(a) in these diseases is unclear. The goal of this study
was to determine whether apo(a)/Lp(a) modiﬁed plasminogen-
dependent leukocyte recruitment in vivo in inﬂammation. Our
ﬁndings of macrophage recruitment are summarized in
Figure 10. By using the mouse models of apo(a)tg mice and
Lp(a) double-transgenic mice, this study provides evidence that
Lp(a) and apo(a) interfere with plasminogen-dependent macro-
phage recruitment in inﬂammation by inhibition of plasminogen
and MMP-9 activation. Reduced macrophage recruitment was
required for protection from aneurysm formation in the apo(a)tg,
Plg/, Plgmut, and Lp(a)tg-AAA resistant mice (plasminogen-
dependent pathway), and was due to decreased plasma plas-
minogen activation, aorta MMP-9 activation, collagen accu-
mulation, and macrophage recruitment in the aorta. However,
dilationof the aorta developed inmicewithvascularmacrophage
recruitment in apo(a)tg:Plg/ and Lp(a)þAAA-susceptible
mice (plasminogen-independent pathway). Although plasma
plasminogen activation was reduced in these mice, MMP-9
activation and macrophage recruitment were not different from
ﬁndings for WT mice, suggesting a plasminogen-
independent pathway of MMP-9 activation, macrophage
recruitment, and AAA formation. Furthermore, we verify an
independent role of apo(a) in neutrophil recruitment to the
injured aorta. Although plasminogen deﬁciency does not
inhibit neutrophil recruitment in TG-induced peritonitis or
CaCl2-induced AAA, apo(a) inhibits neutrophil recruitment
in both inﬂammatory models by inhibiting cytokine release
and reducing entry of neutrophils into the vessel wall. Both
macrophages and neutrophils play important roles in AAA
initiation and in the repair of damaged tissue through
phagocytosis and stimulation of paracrine factors for wound
healing and tissue remodeling after injury.33,34 Our novel
ﬁndings of Lp(a)/apo(a) of MMP-9edependent regulation
of macrophage recruitment and cytokine-dependent
neutrophil recruitment in vivo and the leukocytosis in the
peripheral blood may account for many of the pathological
consequences of elevated Lp(a).
Because mice do not carry the gene for apo(a), transgenic
mice were generated to express human apo(a), and mice with
genotypes of WT, apo(a)tg:Plg/, apo(a)tg:Plg/ [apo(a)tg
in a Plg/ background], and Lp(a)tg:[apo(a)/apoB double
transgenic] were used in this study. There are several reasons
to think that our mouse model is biologically relevant and
offers several advantages: a small apo(a) construct (smaller
isoforms are more pathogenic in patients); expression of
apo(a) at high concentrations; in mice, apo(a) does not
covalently bind to mouse LDL so that effects can be assigned
directly to the apo(a) moiety; and the apo(a) form expressedajp.amjpathol.org - The American Journal of Pathology
Lp(a)/apo(a) and Leukocyte Recruitmenthas high LBS activity, which is associated with pathogenic
effects of apo(a) and its ability to inhibit plasminogen
functions. We also believe our apo(a) mouse model, when
crossed into a plasminogen-deﬁcient and human apoB
background [intact apo(a) assembles Lp(a)], is a useful tool
for dissecting the plasminogen-dependent mechanisms of
Lp(a). The TG-induced peritonitis model is a widely used
inﬂammatory model, and the CaCl2-induced AAA model is
reproducible and induces an inﬂammatory response and
dilation of the aorta in mice with the C57BL/6J background.
Several studies demonstrate that plasminogen-dependent
macrophage recruitment in inﬂammation requires the bind-
ing to receptors (a-enolase, histone H2B, S100A10, and
plasminogen-R KT) on the cell surface and activation of
plasminogen to plasmin.35 Plasminogen deﬁciency or deﬁ-
ciency of speciﬁc receptors abolishes or attenuates plasmin
generation in vivo in inﬂammation and reduces leukocyte
recruitment.35 Although baseline values of plasmin activa-
tion before treatment were not different in apo(a)tg mice
compared with WT mice, plasmin generation was markedly
inhibited by Lp(a)tg or apo(a)tg mice after treatment in the
TG-induced peritonitis and CaCl2-induced AAA inﬂam-
matory models. Lp(a)/apo(a) inhibits binding of plasmin-
ogen to cells and has a marked inhibition of activation after
stimulation in inﬂammation.
MMP-9 activation by plasmin is crucial for macrophage
migration and stem cell mobilization,8,9 and in this study,
plasmin activation of MMP-9 was suppressed by either
apo(a) or Lp(a) in the peritonitis inﬂammatory model.
Although an inverse association of actMMP-9 and Lp(a)
serum level was found in AAA patients,36 there was no direct
evidence of whether Lp(a) or apo(a) regulated MMP-9 acti-
vation. In this study, the modulation of MMP-9 activation by
apo(a) was tested not only in vivo, but also in vitro, and
suggests that apo(a) does not inhibit MMP-9 directly, but via
inhibition of plasminogen activation. MMP-9 activation has
been reported to be important for recovery after hind limb
ischemia, myocardial infarction, and stroke.37,38 The inhibi-
tion of MMP-9 activation by elevated Lp(a)/apo(a) may
impair recovery from CVD. Although the major activator of
MMP-9 is plasmin, in the apo(a)tg:Plg/ mice and Lp(a)tg
AAAþ mice, plasmin was not required for the activation of
MMP-9, suggesting that there may be an alternative activator
for MMP-9. Activation of MMP-9 by other MMPs has been
suggested, but these studies were not evaluated in vivo in
inﬂammation.39,40
Neutrophils are the ﬁrst leukocytes to arrive at the site
of injury, and CXCL1 and CXCL2 are the major cytokine
chemoattractants for neutrophils. Mice treated with anti-
neutrophil antibodies failed to form an aneurysm after
elastase stimulation.41 In Plg/ mice, neutrophils are not
reduced in either the peritonitis or AAA models, sug-
gesting plasminogen is not required for early-stage
neutrophil recruitment. The inhibition of neutrophil
recruitment by apo(a) occurred on either a plasminogen-
replete or a plasminogen-deplete background, indicatingThe American Journal of Pathology - ajp.amjpathol.orgthat the suppressed neutrophil recruitment by apo(a) was
independent of plasminogen. Suppression of neutrophil
recruitment by apo(a) contributed to the inhibition of
aneurysm formation. CXCL1 and CXCL2 expression may
be cell or stimulus dependent.31,32 The major sources of
CXCL1 and CXCL2 are macrophages and neutrophils.
Neither macrophage nor neutrophil number was different
in apo(a)tg and WT mice at the time of cytokine expres-
sion on day 1 after treatment, suggesting that the major
sources of the cytokines were not limiting in the apo(a)tg
mice, and that the release of the cytokines may be
impaired in the apo(a)tg mice. Another potential source of
the cytokines is the resident cells, such as endothelial cells
and smooth muscle cells in the vessel wall.30 Although
circulating CXCL1 and CXCL2 were not different, aortic
CXCL1 and CXCL2 were reduced in apo(a)tg mice
compared with WT mice, suggesting that cytokine secre-
tion by cells in the aorta was regulated by apo(a).
Apo(a)tg mice in the Plgþ/þ background were protected
from AAA formation, but Lp(a)tg mice had a 50% incidence
of AAA, such as the WT mice, and 50% had no AAA-like
apo(a)tg mice. The difference between the AAAþ and
AAA Lp(a)tg mice was not due to a difference in age,
plasmin generation, plasma apo(a), or plasma apoB concen-
tration, or the free/bound apo(a) ratio in the plasma, but may
be related to apo(a) location in the vessel wall. Apo(a) was
predominantly localized in the adventitia of AAA Lp(a)tg
mice, but in the AAAþ Lp(a)tg mice, more apo(a) was
deposited in the intimal/medial layer, where elastic lamina
was disrupted. Because apo(a) localized exclusively in the
adventitial layer of all untreated Lp(a)tg mice, we postulate
that its distribution into the fragmented intimal layer of AAAþ
Lp(a) mice promotes the dilation of the aorta and AAA pro-
gression. The apo(a)tg:Plg/ mice were also susceptible to
AAA formation, and the distribution of apo(a) in the vessel
wall was similar to that of Lp(a)AAAþ mice, with apo(a)
differentially expressed in the intimal/medial layer, rather than
the adventitia, such as the untreated mice.
The roles of apo(a) and Lp(a) in AAA were not identical.
Thompson et al42 investigated the variation of AAA in
inbred mice and found that, although all of the C57BL/6J
mice had aortic dilation, there was a twofold variation in the
amount of dilation. In our study, Lp(a)tg mice were both
susceptible and resistant to AAA formation, and this is
consistent with variation that occurs in human populations.
The observation that not all of apoB colocalized with apo(a)
suggested deposition of free apo(a) in the vessel wall. This
is consistent with the studies in humans of the differential
localization of LDL, Lp(a), and free apo(a) in the athero-
sclerotic lesions.43e46 Numerous studies reported elevated
serum LDL was associated with AAA in patients.47 LDL is
elevated in mice with the human apoB transgene24 and may
contribute to the distinct roles of apo(a) and Lp(a) in AAA
in our mouse model. Our ﬁndings of the mechanism of
apo(a)/Lp(a) in inﬂammation and AAA formation have not
previously been reported.1515
Huang et alClinical Signiﬁcance
Whether Lp(a) is a risk factor in AAA patients has been con-
troversial.48e51 Because our study was performed in mice,
regulation of plasminogen, MMP-9 activation, and cytokine
release will need to be veriﬁed in humans with elevated Lp(a).
Although AAA animal models recapitulate many features of
the humanAAA, the animalmodels are primary inﬂammatory
models that address formation of theAAA.The results of these
models that induce the formation of AAA are short-term and
may not predict the long-term effects that occur in humans. In
patients, AAA is chronic and,more important, it is a process of
atherothrombosis.52,53 In the long-term, Lp(a)/apo(a) may
contribute to anti-ﬁbrinolysis that promotes atherothrombosis
development, leading to deleterious AAA outcome. The pro-
tective role of Lp(a)/apo(a) inhibition of inﬂammatory
cell recruitment, protease activity, and neutrophil chemo-
attractants in early inﬂammation might be counteracted with
its impact on intraluminal thrombus,whichmayoccurwith the
progression of dilation. In addition, the leukocytosis due to the
reduced recruitment in the AAA model may be detrimental.
Studies have provided strong evidence that leukocyte num-
ber54 andmarkers of leukocyte activation55,56 are independent
risk factors for myocardial infarction and other CVDs. As new
therapeutic drugs are developed to reduce elevated Lp(a),
these outcomes can be evaluated.
In conclusion, this study demonstrates that elevated Lp(a)/
apo(a) interferes with plasminogen cell binding and markedly
reduces plasminogen activation and inhibits MMP-9 activa-
tion in inﬂammation. Although previous studies recognized
the consequences of Lp(a) in reduced ﬁbrinolysis, our study
suggests that Lp(a)/apo(a) sufﬁciently inhibits plasminogen
activation and that its downstream pathway, such as MMP-9
activation and macrophage recruitment, is suppressed. Iden-
tiﬁcation of the initial formation and potentially new risk
factors for AAA has been feasible with new techniques to
visualize the intact aorta.57,58 In addition, our study suggests
Lp(a)/apo(a) may also have plasminogen-independent effects
on macrophage recruitment in Lp(a)tg and apo(a):Plg/
mice. Our study suggests targets for AAA, such as variation in
plasminogen activation, MMP-9 activation, leukocyte inﬁl-
tration, and leukocytosis, that may affect the response to
elevated Lp(a). Suppression of MMP-9 activation may serve
as a therapeutic tool. Apo(a) localization in the vessel wall may
be considered a critical indicator for Lp(a)-induced vascular
injury.
Supplemental Data
Supplemental material for this article can be found at
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